

**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 62783

**Manuscript Type:** MINIREVIEWS

**48**  
Prediction models for the development of hepatocellular carcinoma in chronic hepatitis B patients

HCC prediction models

**Abstract**

Chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) is a major health problem in Asian Pacific regions. Antiviral therapy reduces, but does not completely prevent, HCC development. Thus, there is a need for accurate risk prediction to assist prognostication, decisions on the need for antiviral therapy and HCC surveillance. A few risk scores have been developed to predict the occurrence of HCC in CHB patients. Initially, the scores were derived from untreated CHB patients. With the development and extensive clinical application of nucleos(t)ide analogs (NA), the number of risk

**Match Overview**

Match 1 of 1

1	<b>Internet</b> 93 words crawled on 14-Jul-2019 <a href="http://www.oncotarget.com">www.oncotarget.com</a>	2%
2	<b>Internet</b> 88 words crawled on 09-Oct-2020 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	1%
3	<b>Internet</b> 80 words crawled on 09-Dec-2017 <a href="http://ascopubs.org">ascopubs.org</a>	1%
4	<b>Crossref</b> 77 words Vincent Wai-Sun Wong, Harry L.A. Janssen. "Can we use... HCC risk scores to individualize surveillance in chronic hep	1%
5	<b>Crossref</b> 74 words Hwai-I Yang, Ming-Lun Yeh, Grace L Wong, Cheng-Yuan P eng et al. "Real-World Effectiveness From the Asia Pacific	1%
6	<b>Crossref</b> 60 words Jung Hwan Yu, Young Ju Suh, Young-Joo Jin, Nae-Yun He o, Ji Woong Jang, Chan Ran You, Hyun Young An, Jin-Wo	1%
7	<b>Crossref</b> 59 words Ji Hyun Kim, Young Don Kim, Minjong Lee, Baek Gyu Jun et al. "Modified PAGE-B score predicts the risk of hepatoc...	1%
8	<b>Crossref</b> 56 words Tae Seop Lim, Hyun Woong Lee, Jung Il Lee, In Hee Kim e t al. "Predictive score for hepatocellular carcinoma after h...	1%



Prediction models for the development of hepatocellular carcinoma



ALL

IMAGES

VIDEOS

1,270,000 Results

Any time ▼

## Prediction models of hepatocellular carcinoma development ...

<https://pubmed.ncbi.nlm.nih.gov/27729738>

Herein, we summarized various HCC **prediction models**, including IPM (Individual **Prediction Model**), CU-HCC (Chinese University-HCC), GAG-HCC (Guide with Age, Gender, HBV DNA, Core Promoter Mutations and Cirrhosis-HCC), NGM-HCC (Nomogram-HCC), REACH-B (Risk Estimation for **Hepatocellular Carcinoma in Chronic Hepatitis B**), and Page-B score.

**Cited by:** 21

**Author:** Hye Won Lee, Sang Hoon Ahn

**Publish Year:** 2016

## Prediction model for hepatocellular carcinoma risk in ...

<https://www.ncbi.nlm.nih.gov/pubmed/30694912>

BACKGROUND/AIM: Accurate assessment of **hepatocellular carcinoma** (HCC) risk in **chronic hepatitis B** (CHB) **patients** receiving entecavir (ETV)/tenofovir disoproxil fumarate (TDF) is likely to play a pivotal role in post-treatment follow-up strategy. We aimed to develop a simple and reliable predictive **model** for HCC risk in these **patients**.

**Cited by:** 7

**Author:** Jung Hwan Yu, Young Ju Suh, Young-Joo J...

**Publish Year:** 2019

## Prediction of hepatocellular carcinoma development by ...

<https://pubmed.ncbi.nlm.nih.gov/21876190>

**Prediction of hepatocellular carcinoma development** by plasma ADAMTS13 in **chronic hepatitis B** and C. Plasma ADAMTS13 as a **potential marker of hepatic stellate cells** may be useful in the **prediction of hepatocarcinogenesis**. Plasma ADAMTS13 as a potential marker of hepatic stellate cells may be useful in the prediction of hepatocarcinogenesis.

**Cited by:** 11

**Author:** Hitoshi Ikeda, Ryosuke Tateishi, Kenichiro ...



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

982,000 Results

Any time ▾

Open links in new tab



## Prediction models of hepatocellular carcinoma development ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC27729738>

Oct 07, 2016 · Herein, we summarized various HCC **prediction models**, including IPM (Individual **Prediction Model**), CU-HCC (Chinese University-HCC), GAG-HCC (Guide with Age, Gender, HBV DNA, Core Promoter Mutations and Cirrhosis-HCC), NGM-HCC (Nomogram-HCC), REACH-B (Risk Estimation for **Hepatocellular Carcinoma in Chronic Hepatitis B**), and Page-B score.

Cited by: 22

Author: Hye Won Lee, Sang Hoon Ahn

Publish Year: 2016

## Prediction of hepatocellular carcinoma development by ...

<https://pubmed.ncbi.nlm.nih.gov/21876190>

**Prediction of hepatocellular carcinoma development** by plasma ADAMTS13 in **chronic hepatitis B** and C. Plasma ADAMTS13 as a **potential marker of hepatic stellate cells** may be useful in the **prediction of hepatocarcinogenesis**. Plasma ADAMTS13 as a potential marker of hepatic stellate cells may be useful in the prediction of hepatocarcinogenesis.

Cited by: 11

Author: Hitoshi Ikeda, Ryosuke Tateishi, Kenichiro ...

Publish Year: 2011

## Development of prediction model for hepatocellular ...

<https://oncologypro.esmo.org/meeting-resources/...> ▾

Nov 23, 2019 · This retrospective cohort study was conducted to **develop** a risk estimate **model** of **HCC** in **chronic hepatitis B (CHB) patients**. Our **prediction model** was derived from data obtained in 2,208 CHB **patients** from Chulabhorn Hospital, Thailand. (Follow-up period: 2011-2017). Forward stepwise multivariable parametric regression **model** was applied to obtain coefficients for each predictor.

## Feasibility of Dynamic Risk Prediction for Hepatocellular ...

<https://pubmed.ncbi.nlm.nih.gov/28865176>

Background & aims: Several risk **prediction models** for **hepatocellular carcinoma (HCC) development** are available. We explored whether the use of risk **prediction models** can dynamically **predict HCC development** at different time points in **chronic hepatitis B (CHB) patients**. Methods: Between 2006 and 2014, 1397 **CHB patients** were recruited. All **patients** underwent serial transient elastography at ...

Cited by: 11

Author: Mi Young Jeon, Hye Won Lee, Seung Up Ki...

Publish Year: 2018

## Hepatocellular Carcinoma

Medical Condition

The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

 Rare (Fewer than 200,000 cases per year in US)

 May be preventable by vaccine

 Often requires lab test or imaging

 Treatment from medical professional advised

 Can last several months or years

Caused mainly due to the chronic infection of the liver or DNA mutation of the liver cells. Characterized by unexplained weight loss, upper abdominal pain and yellowing of the skin. Treatment options include hepatectomy, target drug delivery and the use of radiation to kill the cancerous cells.

## Symptoms

The early stages of the disease do not present any symptoms but in the later stages the symptoms which are noted are as follows:

- Upper abdominal pain
- Weight loss
- Jaundice
- Fluid in the abdomen
- Liver failure

## Treatments

Treatment option which is employed depends on the stage of the condition, size and location of the tumor.

### Medication

- Chemotherapy: Therapy where the drugs are used to kill the cancer cells.  
5-Fluorouracil · Capecitabine · Irinotecan · Oxaliplatin
- Target drug delivery: Drugs which are target oriented help in slowing